Prostate cancer · Konu · Gümüşhane Üniversitesi

Sürdürülebilir Kalkınma Amaçları

Yazarlar

Yayınlar

Yeniden eskiye Eskiden yeniye

MakaleAçık Erişim2025Scopus SJRQ2/r/gumushane/13646
A novel equation synthesis for estimating resting energy expenditure in prostate cancer patients
Tek, Nilüfer Acar; Koçak, Tevfik; Yeşil, Süleyman; Sözen, Tevfik Sinan
Background: An accurate calculation of energy expenditure (REE) is necessary for estimating energy needs in malign prostate cancer. The purpose of this research was to evaluate the accuracy of the established novel equation for predicting REE in malign and benign prostate patients versus the accuracy of the previously used predictive equations based on REE measured by indirect calorimetry. Methods: The study was conducted as a cross-sectional case-control study and between December 2020 and May 2021 with 40 individuals over the age of 40 who applied to the Urology Clinic of Gazi University Faculty of Medicine. Subjects with 41 malign prostate and 42 benign prostate patients were both over the age of 40 (65.3 ± 6.30 years) and recruited for the study. Cosmed-FitMate GS Indirect Calorimetry with Canopyhood (Rome, Italy) was used to measure REE. A full body composition analysis and anthropometric measurements were taken. Clinical trial number: Not applicable. Results: Malign prostate group PSA Total and measured REE values (4.93 ± 5.44 ng/ml, 1722.9 ± 272.69 kcal/d, respectively) were statistically significantly higher than benign group (1.76 ± 0.73 ng/ml, 1670.5 ± 266.76 kcal/d, respectively) (p = 0.022). Malign prostate group (MPG) and benign prostate group (BPG) have the highest percentage of the accurate prediction value of Eq. 80.9% (novel equation MPG) and 64.2% (novel equation BPG). The bias of the equations varied from − 36.5% (Barcellos II Equation) to 19.2% (Mifflin-St. Jeor equation) for the malign prostate group and varied from − 41.1% (Barcellos II Equation) to 17.7% (Mifflin-St. Jeor equation) in the benign prostate group. The smallest root mean squared error (RMSE) values in the malign and benign prostate groups were novel equation MPG (149 kcal/d) and novel equation BPG (202 kcal/d). The new specific equation for malign prostate cancer: REE = 3192,258+ (208,326* body weight (WT)) - (20,285* height (HT)) - (187,549* fat free mass (FFM)) - (203,214* fat mass (FM)) + (4,194* prostate specific antigen total (PSAT)). The new specific equation for the benign prostate group is REE = 615,922+ (13,094*WT). Bland-Altman plots reveal an equally random distribution of novel equations in the malign and benign prostate groups. Conclusions: Previously established prediction equations for REE may be inconsistent. Utilising the PSAT parameter, we formulated novel energy prediction equations specific to prostate cancer. In any case, the novel predictive equations enable clinicians to estimate REE in people with malign and benign prostate groups with sufficient and most acceptable accuracy.
AtıfScopus1WoS1OpenAlex1
İncele
MakaleYayıncıda açık erişim2025Scopus SJRQ2/r/gumushane/10483
Serum neopterin and kynurenine as predictive and prognostic biomarkers in prostate cancer: the role of dietary inflammatory index and biomarker interactions
Icer, Mehmet Arif; Koçak, Tevfik; Acar-Tek, Nilufer; Yesil, Suleyman; Icer, Yusuf
Background It has been shown that neopterin levels in various body fluids can help predict the diagnosis of different malignancies. Although many studies have investigated the roles of serum neopterin concentrations, tryptophan metabolism, and the dietary inflammation index (DII) in various cancers, the connection between these factors and prostate cancer (PC) remains uncertain. The aim of this study was to investigate the predictive and prognostic roles of serum neopterin, and kynurenine levels, along with the kynurenine-to-tryptophan ratio (KTR) and DII in prostate cancer. Methods This study was conducted with 57 newly diagnosed prostate cancer patients, 55 benign prostate hyperplasia patients, and 56 healthy male individuals in the control group, all aged 40 years and older. Participants had specific anthropometric measurements taken, and three-day food records were kept. DII was calculated based on data for thirty-four available nutrients by using food records. Serum levels of neopterin, kynurenine, tryptophan, tumor necrosis factor alpha (TNF-alpha), and interferon-gamma (IFN-gamma) were measured using an enzyme-linked immunosorbent assay (ELISA) method. Results Serum neopterin (11.79 +/- 6.09), kynurenine (1655.48 +/- 1122.04), TNF-alpha (221.59 +/- 232.06) and IFN-gamma (137.68 +/- 107.11) levels were higher in the malignant group than in both the control (2.72 +/- 0.76, 352.40 +/- 69.33, 223.94 +/- 226.67, and 23.03 +/- 7.28, respectively) and benign groups (3.17 +/- 0.74, 377.94 +/- 109.05, 179.61 +/- 224.36, and 25.63 +/- 7.50, respectively) (p < 0.05). Another result of our study is that in the malignant group, serum neopterin levels exhibited significant positive correlations with serum kynurenine (r = 0.80, p < 0.0001), IFN-gamma (r = 0.86, p < 0.0001) and TNF-alpha levels (r = -0.27, p = 0.0453) and DII (r = 0.30, p = 0.0229), while they exhibited weak correlations with serum PSA, and other diet parameters. Additionally, kynurenine was the only parameter showing significant differences in mean values concerning surgical margins (p < 0.05). Conclusions The findings of this study support the hypothesis that serum neopterin and specific tryptophan catabolites (e.g., kynurenine), could serve as predictive and prognostic biomarkers for prostate cancer diagnosis. However, our results do not support the hypothesis that DII and certain dietary factors play a direct role in the development or diagnosis of prostate cancer.
AtıfScopus3WoS3OpenAlex2
İncele
MakaleAçık Erişim2025Scopus SJRQ2/r/gumushane/10402
Could GSTP1, PTEN and NKX3.1 gene expression be novel markers in the relationship between prostate cancer and epigenetics?
Koçak, Tevfik; Acar-Tek, Nilufer; Yesil, Suleyman; Ergün, Mehmet Ali; Icer, Yusuf
Background: Although numerous treatment modalities exist for Prostate Cancer (PCa) with a complex pathophysiology, a significant worldwide health concern for males, early identification remains the paramount factor influencing disease prognosis. Proposed new biomarkers, including GSTP1, PTEN, and NKX3.1, may provide predictive and prognostic functions, hence enhancing the efficacy of PSA in diagnosing prostate cancer. Epigenetic variables associated with nutrition influence the blood gene expression levels of the new biomarkers GSTP1, PTEN, and NKX3.1. This study aimed to elucidate the correlation between nutrition-related epigenetic variables and the expression of the tumor suppressor genes GSTP1, PTEN, and NKX3.1 in benign prostate and prostate cancer patients. Methods: This study was conducted with 41 newly diagnosed prostate cancer and 42 benign prostate patients, all aged 40 years and older. Participants had specific anthropometric measurements taken, and seven-day food records were kept. Serum levels of novel biochemical markers GSTP1, PTEN, and NKX3.1 were measured using an Enzyme-Linked Immunosorbent Assay (ELISA) method. Expression analyses of tumor-protective GSTP1, PTEN, and NKX3.1 genes were performed on prostate tissues obtained from fresh prostate biopsies taken from the groups and were associated with nutritional status. Results: A significant relationship was found between the serum levels of GSTP1, PTEN, and NKX3.1, which are important in the formation and treatment of prostate cancer, and Gleason grade, tumor stage, and surgical margin status (p < 0.05). However, significant relationships were found between many macro and micronutrients obtained from the dietary pattern and effective in epigenetic pathways and GSTP1, PTEN, and NKX3.1 gene expressions (p < 0.05). Conclusions: The findings of this investigation corroborated the notion that prospective novel markers, including GSTP1, PTEN, and NKX3.1, may serve predictive and prognostic functions in prostate cancer, hence enhancing the efficacy of PSA in its diagnosis. Dietary trends may influence the optimization of many epigenetic processes. Targeted therapeutic nutritional interventions designed to enhance gene expression will facilitate the formulation of prostate cancer prevention methods.
İncele
MakaleYayıncıda açık erişim2023Scopus SJRQ4/r/gumushane/11791
Postoperative symptom management perceptions and coping experiences of individuals with prostate cancer
Kazımoğlu, Hatem; Ulutaşdemir, Nilgün; Kulakaç, Nurşen; Uzun, Sevda
Objective: This study aims to examine in depth the perceptions of postoperative symptom management and coping experiences of individuals with prostate cancer. Material-Method: The study was conducted with 15 individuals with prostate cancer using a phenomenological research design, which is a qualitative research design. Interviews were conducted via the WhatsApp application. Results: The data were analysed using Colaizzi's phenomenological method. In the data analysis, two categories, five main themes, and 15 sub-themes emerged. In the category of symptom management perception, there are themes of pain management processes, the use of complementary and alternative therapies and practices to cope with symptoms and improve quality of life. In the category of coping experiences, the themes of individual coping, interpersonal relations, and productivity were obtained. Conclusion: Our study suggests that individuals with prostate cancer have difficulty in symptom management in the postoperative coping process, but they managed them effectively with the support of their spouse, family, and health care professionals.
AtıfScopus1WoS1OpenAlex1
İncele
MakaleAçık Erişim2022/r/gumushane/16448
Clinical Preferences of Turkish Urologists in Screening and Diagnosis of Prostate Cancer and Adherence to European Association of Urology Guidelines
Yildiz, Huseyin Alperen; Demirkiran, Engin Denizhan; Madendere, Serdar; Deger, Muslim Dogan
Objective: To compare the clinical preferences of urologists in prostate cancer screening and diagnosis with current guideline recommendations.Materials and Methods: The study is based on an online survey that consists of 21 single response or multiple response questions. By e-mail, 2,305 certified urologists in active practice as well as urology residents in their last year of training were invited to participate in the study. Descriptive statistics were used to analyze practice patterns and demographics. The respondents were divided into groups based on their experience in urology, hospital type and academic title.Results: Our results show that preferences of the majority of urologists conflicts with recommendations of European Association of Urology Prostate Cancer Guidelines regarding prostate biopsy method, management of a patient with high prostate-specific antigen value, use of additional test and performance scoring systems, role of multiparametric prostate magnetic resonance imaging.Conclusion: Urologists act in the direction of their habits or clinical experience rather than current guidelines regardless of their experience. Both clinicians and professional organizations should work on what can be done about the reflection of rapidly changing scientific knowledge on the field and the improvement of the health service provided.
AtıfWoS1OpenAlex1
İncele
MakaleAçık Erişim2021/r/gumushane/16379
Urologists' Role and Attitude in the Systemic Treatment of Urologic Cancers
Madendere, Serdar; Deger, Muslim Dogan; Demirkiran, Engin Denizhan; Yildiz, Huseyin Alperen
Objective: The goal of this study was to investigate Turkish urologists' role and attitude toward the systemic treatment of urologic cancers. Materials and Methods: An 18-item survey was e-mailed to 2305 certified Turkish urologists. The survey included questions designed to evaluate urologists' knowledge of chemotherapy procedures and their ability to manage complications, as well as how many of them perform systemic therapies and believe urologists should perform these therapies for urologic cancers. Results: We evaluated 305 responses. Most urologists (89.6%) perform hormonotherapy for prostate cancers. Further, the majority refer patients to medical oncologists for chemotherapy. Moreover, 65.9%, 70.8%, and 72.1% of the urologists believe that only medical oncologists should deliver chemotherapy for prostate, bladder, and testicular cancers, respectively. Only 23.9% of urologists believe they are competent to perform chemotherapy, while 16.7% believe they are capable of dealing with chemotherapy complications. Conclusion: Turkish urologists have a lack of performance and interest in administering systemic therapies in urologic cancers. We want to emphasize that urology is more than just surgery. Urologists should be involved in all stages of cancer treatment.
AtıfWoS1OpenAlex1
İncele
MakaleAçık Erişim2019Scopus SJRQ3/r/gumushane/10629
Prostate volume effect on Gleason score upgrading in active surveillance appropriate patients
Çamur, Emre; Coskun, Alper; Kavukoglu, Ovunc; Can, Utku; Kara, Onder; Çamur, Arzu Develi; Sarica, Kemal; Narter, Kamil Fehmi
Introduction: Gleason Score (GS) upgrading rates in the literature are reported to be around 33-45%. The relationship between prostate volume and GS upgrading should be defined, aiming to reduce upgrading rates in patients with low risk groups who are eligible for active surveillance (AS) or minimally invasive treatment, by varying biopsy cores, or lengths of cores according to prostate volumes. In this regard, the aim of our study was to establish the relationship between prostate volume and GS upgrading. Materials and methods: We retrospectively analyzed the medical records of 78 patients, who were appropriate for AS between 2011-2016 at our hospital. Inclusion criteria were patient age under 65 years, PSA level under 10 ng/ml, GS (3 + 3) or (3 + 4), and 3 or less positive cores, clinical stages <= T2. GS increase in radical prostatectomy specimen was considered as 'upgrading' and in addition, score reported by biopsy as 3 + 4 but in surgical specimen as 4 + 3 were also considered as 'upgrading'. The effect of prostate volume on Gleason grade upgrading was examined by calculating upgrading rates separately for patients with prostate volume 30 ml or less, those with 30 to 60 ml, and those over 60 ml. Results: As a result of the analysis of the data, upgrading was seen in 35 (44.8%) of 78 patients included in the study. In the cohort mean prostate volume was 49.8 (+/- 26.3) ml. Twenty-two patients (28.2%) had prostate volume 30 ml or less, 34 (43.6%) 30 to 60 ml, and 22 (28.2%) 60 ml or more. The patients were divided into two groups as those with and without GS upgrading. Between the groups prostate volume and prostate volume range (0-30/31-60/> 60) were not significantly different (p value > 0.05). Conclusions: Gleason grade upgrading causes patients to be classified in a lower risk group than they actually are, and may lead to inappropriate treatment. This condition has a direct effect on the decision of active surveillance. Therefore, it is important to define the factors that can predict GS upgrading in active surveillance appropriate patients. In this study, we found that prostate volume has no significant effect on upgrading in active surveillance appropriate patients.
AtıfWoS6OpenAlex9
İncele